Literature DB >> 27035242

Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.

Neal L Benowitz1, Gideon St Helen, Delia A Dempsey, Peyton Jacob, Rachel F Tyndale.   

Abstract

OBJECTIVE: The rate of nicotine metabolism, determined primarily by CYP2A6 activity, influences tobacco dependence and smoking-induced disease risk. The prevalence of CYP2A6 gene variants differs by race, with greater numbers in African Americans compared with Caucasians. We studied nicotine disposition kinetics and metabolism by the CYP2A6 genotype and enzymatic activity, as measured by the nicotine metabolite ratio (NMR), in African American smokers.
METHODS: Participants were administered intravenous infusions of deuterium-labeled nicotine and cotinine. Plasma and urine concentrations of nicotine and metabolites were measured and pharmacokinetic parameters were estimated.
RESULTS: Pharmacokinetic parameters and urine metabolite excretion data were analyzed by CYP2A6 genotype and by NMR. A number of gene variants were associated with markedly reduced nicotine and cotinine clearances. NMR was strongly correlated with nicotine (r=0.72) and cotinine (r=0.80) clearances. Participants with higher NMR excreted significantly greater nicotine C-oxidation and lower non-C-oxidation products compared with lower NMR participants.
CONCLUSION: CYP2A6 genotype, NMR, and nicotine pharmacokinetic data may inform studies of individual differences in smoking behavior and biomarkers of nicotine exposure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035242      PMCID: PMC4892970          DOI: 10.1097/FPC.0000000000000222

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  35 in total

1.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

2.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Authors:  Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

3.  Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

4.  Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.

Authors:  F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-04-02       Impact factor: 6.875

Review 5.  Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.

Authors:  Viba Malaiyandi; Edward M Sellers; Rachel F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2005-03       Impact factor: 6.875

Review 6.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

Review 7.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

8.  Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans.

Authors:  P Jacob; L Yu; M Wilson; N L Benowitz
Journal:  Biol Mass Spectrom       Date:  1991-05

Review 9.  Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.

Authors:  Jill C Mwenifumbo; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2007-10       Impact factor: 2.533

10.  Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.

Authors:  Mark Piliguian; Andy Z X Zhu; Qian Zhou; Neal L Benowitz; Jasjit S Ahluwalia; Lisa Sanderson Cox; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2014-02       Impact factor: 2.089

View more
  17 in total

Review 1.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

2.  Low-level maternal exposure to nicotine associates with significant metabolic perturbations in second-trimester amniotic fluid.

Authors:  S Taylor Fischer; Loukia N Lili; Shuzhao Li; ViLinh T Tran; Kim B Stewart; Charles E Schwartz; Dean P Jones; Stephanie L Sherman; Judith L Fridovich-Keil
Journal:  Environ Int       Date:  2017-07-30       Impact factor: 9.621

3.  Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).

Authors:  Cindy M Chang; Brian L Rostron; Joanne T Chang; Catherine G Corey; Heather L Kimmel; Connie S Sosnoff; Maciej L Goniewicz; Kathryn C Edwards; Dorothy K Hatsukami; Yuesong Wang; Arseima Y Del Valle-Pinero; Maocheng Yang; Mark J Travers; Stephen Arnstein; Kristie Taylor; Kevin Conway; Bridget K Ambrose; Nicolette Borek; Andrew Hyland; Lanqing Wang; Benjamin C Blount; Dana M van Bemmel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-07       Impact factor: 4.254

4.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

Review 5.  Epigenome-based cancer risk prediction: rationale, opportunities and challenges.

Authors:  Martin Widschwendter; Allison Jones; Iona Evans; Daniel Reisel; Joakim Dillner; Karin Sundström; Ewout W Steyerberg; Yvonne Vergouwe; Odette Wegwarth; Felix G Rebitschek; Uwe Siebert; Gaby Sroczynski; Inez D de Beaufort; Ineke Bolt; David Cibula; Michal Zikan; Line Bjørge; Nicoletta Colombo; Nadia Harbeck; Frank Dudbridge; Anne-Marie Tasse; Bartha M Knoppers; Yann Joly; Andrew E Teschendorff; Nora Pashayan
Journal:  Nat Rev Clin Oncol       Date:  2018-02-27       Impact factor: 66.675

6.  Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking.

Authors:  Neal L Benowitz; Gideon St Helen; Natalie Nardone; Lisa Sanderson Cox; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

7.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

8.  Differential effects of nicotine delivery rate on subjective drug effects, urges to smoke, heart rate and blood pressure in tobacco smokers.

Authors:  Kevin P Jensen; Gerald Valentine; Ralitza Gueorguieva; Mehmet Sofuoglu
Journal:  Psychopharmacology (Berl)       Date:  2020-01-29       Impact factor: 4.530

9.  An Exome-Wide Association Study Identifies New Susceptibility Loci for Age of Smoking Initiation in African- and European-American Populations.

Authors:  Keran Jiang; Zhongli Yang; Wenyan Cui; Kunkai Su; Jennie Z Ma; Thomas J Payne; Ming D Li
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

10.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.